ROTTAPHARM
🇫🇷France
Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome
Not Applicable
Completed
- Conditions
- Metabolic SyndromeInsulin-resistanceLeft Ventricular Hypertrophy
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Armolipid Plus
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 159
- Registration Number
- NCT02295176
- Locations
- 🇮🇹
Ferruccio Galletti, Naples, Italy
🇮🇹Domenico Bonaduce, Naples, Italy
🇮🇹Giuseppe Schillaci, Terni, Italy
Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C
Phase 2
Withdrawn
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Rottapharm
- Registration Number
- NCT01871662
- Locations
- 🇪🇬
Al-Manial University Hospital, Kasr El-Aini Faculty Medicine, Cairo University, Cairo, Egypt
Estromineral Serena Plus and Symptomatic Menopause
Not Applicable
- Conditions
- Menopause
- Interventions
- Dietary Supplement: Estromineral Serena PlusDietary Supplement: Estromineral
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 300
- Registration Number
- NCT01730989
- Locations
- 🇮🇹
Siena University, Siena, Italy
Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients
Phase 2
Terminated
- Conditions
- HCV Recurrence After Liver Transplantation
- Interventions
- Drug: PlaceboDrug: Silibinin
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 14
- Registration Number
- NCT01535092
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Phase 2
Terminated
- Conditions
- Hepatitis C Virus Recurrence
- Interventions
- Drug: SalineDrug: Silibinin (Legalon-SIL)
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 20
- Registration Number
- NCT01518933
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Italy
Armolipid Plus and Metabolic Syndrome
Not Applicable
Completed
- Conditions
- Metabolic Syndrome
- Interventions
- Dietary Supplement: Armolipid Plus
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2010-09-02
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 66
- Registration Number
- NCT01087632
- Locations
- 🇮🇹
Federico II University - Department of Internal Medicine, Naples, Italy
DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Phase 3
Completed
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-05-14
- Lead Sponsor
- Rottapharm
- Registration Number
- NCT00220090
- Locations
- 🇬🇧
Academic Department of Medicine Wythenshawe Hospital, Manchester, United Kingdom
Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis
Phase 3
Completed
- Conditions
- Knee Osteoarthritis
- First Posted Date
- 2005-05-10
- Last Posted Date
- 2006-09-19
- Lead Sponsor
- Rottapharm
- Target Recruit Count
- 300
- Registration Number
- NCT00110474
- Locations
- 🇵🇹
Hospital Universitario de Coimbra, Coimbra, Portugal
🇵🇹Hospital Egaz Moniz, Lisboa, Portugal
🇵🇹Hospital Conde do Bertiandos, Ponte de Lima, Portugal
© Copyright 2025. All Rights Reserved by MedPath